In vivo activity of mutacin B-Ny266
Authors: Mota-Meira, Marilaine1; Morency, Helene2; Lavoie, Marc C.1
Source: Journal of Antimicrobial Chemotherapy, Volume 56, Number 5, November 2005 , pp. 869-871(3)
Publisher: Oxford University Press
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Abstract:
Objectives: The objective of this study was to assess the in vivo activity of mutacin B-Ny266 (a bacteriocin produced by Streptococcus mutans) in order to eventually use it as an antibiotic.Methods: Intraperitoneal infection was induced with a methicillin-susceptible Staphylococcus aureus strain in mice. Some of the mice were simultaneously injected intraperitoneally with mutacin B-Ny266, some with the vehicle only and some with vancomycin.Results: While there was 70 and 100% mortality in the control groups of mice, no mortality was observed in the mice injected with vancomycin or mutacin B-Ny266.Conclusions: The results presented here show, for the first time, the in vivo efficacy of a mutacin (B-Ny266) against an experimental intraperitoneal infection by S. aureus in a mouse model.Keywords: antimicrobial peptides; lantibiotics
Document Type: Research article
DOI: 10.1093/jac/dki295
Affiliations: 1: Department of Biological and Chemical Sciences, Faculty of Pure and Applied Sciences, The University of the West Indies, Cave Hill Campus, PO Box 64, Bridgetown, Barbados; 2: Département de Biochimie et Microbiologie, Faculté des Sciences et de Génie, Université Laval, Québec, Canada
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Click here for Page Help